

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Shi-Lung Lin et al.

Serial No: 09/920,342

Confirmation No.: 4134

Filed: August 1, 2001

For: GENE SILENCING USING mRNA-CDNA
HYBRIDS

Art Unit: 1635

Examiner: Kimberly Chong

I hereby certify that this correspondence
is being transmitted via electronic filing
to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

November 27, 2007

Date of Deposit

Diane Zynn

Name

 11/27/07

Signature

Date

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


In response to the Restriction Requirement dated August 9, 2007, Applicant elects for prosecution the bcl-2 sequence amplified by SEQ ID Nos. 8 and 9 as the target gene sequence for claims 36 and 60.

If there are any fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-1314.

Respectfully submitted,

HOGAN & HARTSON L.L.P.

Date: November 27, 2007

By: 
Lawrence J. McClure
Registration No. 44,228
Attorney for Applicant

1999 Avenue of the Stars, Suite 1400
Los Angeles, California 90067
Telephone: 310-785-4600
Facsimile: 310-785-4601